| abstract |
A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity for the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications. |